HK1203413A1 - Methods and compositions for treating ineffective erythropoiesis - Google Patents
Methods and compositions for treating ineffective erythropoiesisInfo
- Publication number
- HK1203413A1 HK1203413A1 HK15104178.9A HK15104178A HK1203413A1 HK 1203413 A1 HK1203413 A1 HK 1203413A1 HK 15104178 A HK15104178 A HK 15104178A HK 1203413 A1 HK1203413 A1 HK 1203413A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- ineffective erythropoiesis
- treating ineffective
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547932P | 2011-10-17 | 2011-10-17 | |
PCT/US2012/060650 WO2013059347A1 (en) | 2011-10-17 | 2012-10-17 | Methods and compositions for treating ineffective erythropoiesis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203413A1 true HK1203413A1 (en) | 2015-10-30 |
Family
ID=48141315
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104178.9A HK1203413A1 (en) | 2011-10-17 | 2015-04-30 | Methods and compositions for treating ineffective erythropoiesis |
HK18109792.1A HK1250341A1 (zh) | 2011-10-17 | 2018-07-30 | 用於治療無效性紅細胞生成的方法和組合物 |
HK18112295.7A HK1252940A1 (zh) | 2011-10-17 | 2018-09-26 | 用於治療無效性紅細胞生成的方法和組合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18109792.1A HK1250341A1 (zh) | 2011-10-17 | 2018-07-30 | 用於治療無效性紅細胞生成的方法和組合物 |
HK18112295.7A HK1252940A1 (zh) | 2011-10-17 | 2018-09-26 | 用於治療無效性紅細胞生成的方法和組合物 |
Country Status (13)
Country | Link |
---|---|
US (4) | US20130243743A1 (de) |
EP (3) | EP3520805B1 (de) |
JP (4) | JP6092883B2 (de) |
KR (4) | KR20140084211A (de) |
CN (3) | CN107837390A (de) |
AU (4) | AU2012326207B2 (de) |
BR (3) | BR112014009528B1 (de) |
CA (1) | CA2852683A1 (de) |
DK (1) | DK3520805T3 (de) |
EA (2) | EA202090053A3 (de) |
ES (2) | ES2741477T3 (de) |
HK (3) | HK1203413A1 (de) |
WO (1) | WO2013059347A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CN103432568A (zh) | 2005-11-23 | 2013-12-11 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
TW201919685A (zh) | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
CA2764890A1 (en) | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
AU2010263182B2 (en) | 2009-06-12 | 2016-05-12 | Acceleron Pharma Inc. | Truncated ActRIIB-Fc fusion proteins |
WO2011031901A1 (en) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
KR102279522B1 (ko) | 2012-11-02 | 2021-07-19 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
AU2015231022B2 (en) * | 2014-03-21 | 2021-02-04 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin B and/or GDF11 |
JP6649895B2 (ja) * | 2014-04-18 | 2020-02-19 | アクセルロン ファーマ, インコーポレイテッド | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 |
TN2016000553A1 (en) * | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
RS64214B1 (sr) * | 2014-12-03 | 2023-06-30 | Celgene Corp | Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma |
KR20180006386A (ko) | 2015-04-22 | 2018-01-17 | 얼라이브젠 유에스에이 인코포레이티드 | 신규한 근육 소모 질환 치료용 하이브리드 actriib 리간드 트랩 단백질 |
US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
EP3298034A4 (de) | 2015-05-20 | 2019-02-13 | Celgene Corporation | In-vitro-zellkulturverfahren zur beta-thalassämie mittels fallen von activin-typ-ii-rezeptor-liganden |
US11123430B2 (en) * | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
CN108697793B (zh) | 2015-11-23 | 2023-08-01 | 阿塞勒隆制药公司 | 治疗眼睛疾病的方法 |
EP3523328A4 (de) * | 2016-10-05 | 2020-04-01 | Acceleron Pharma Inc. | Variante actriib-proteine und verwendungen davon |
CN110461349A (zh) | 2016-11-10 | 2019-11-15 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
CN111050770A (zh) * | 2017-06-14 | 2020-04-21 | 细胞基因公司 | 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法 |
KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
AU2019206634B2 (en) | 2018-01-12 | 2024-06-27 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
US5807839A (en) * | 1997-04-15 | 1998-09-15 | Advanced Viral Research Corp. | Method for stimulating red blood cell production |
DE60027135T2 (de) | 1999-01-21 | 2007-01-11 | Metamorphix, Inc. | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
JP2006510606A (ja) * | 2002-10-15 | 2006-03-30 | セルジーン・コーポレーション | 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物 |
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TW201919685A (zh) * | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
AU2010282361B2 (en) * | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
-
2012
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/de active Active
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Application Discontinuation
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en active Application Filing
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active IP Right Cessation
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/de active Active
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 EP EP21153891.3A patent/EP3875104A1/de active Pending
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active IP Right Grant
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Application Discontinuation
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
-
2015
- 2015-04-30 HK HK15104178.9A patent/HK1203413A1/xx unknown
-
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
-
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
-
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252940A1 (zh) | 用於治療無效性紅細胞生成的方法和組合物 | |
HK1214521A1 (zh) | 用於治療蛋白質病的組合物和方法 | |
HK1201475A1 (en) | Methods and compositions for treating pain | |
IL227429A0 (en) | The components and methods of cancer treatment | |
EP2755482A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
EP2684167A4 (de) | Zusammensetzungen und verfahren zur behandlung von erkrankungen | |
ZA201404187B (en) | Compositions and methods for treating dental conditions | |
EP2771341A4 (de) | Neue zusammensetzungen und verfahren zur behandlung von krebs | |
HK1190936A1 (zh) | 治療代謝綜合徵的方法和配方 | |
DK3292875T3 (en) | Compositions and methods for treating diseases | |
EP2766009A4 (de) | Verfahren und zusammensetzungen zur hautbehandlung | |
EP2800579A4 (de) | Verfahren und zusammensetzungen zur behandlung von diabetes | |
HRP20180687T1 (hr) | Kompozicije i metode za liječenje celijakije spru | |
EP2590674A4 (de) | Zusammensetzungen und verfahren zur influenza-behandlung | |
IL232648A0 (en) | Preparations and methods for treating glioma | |
HK1208598A1 (en) | Methods and compositions for treating pain | |
IL229231A0 (en) | Preparations and methods for the treatment of cancer | |
EP2723346A4 (de) | Zusammensetzungen und verfahren zur behandlung von lausbefall | |
ZA201308683B (en) | Methods and compositions suitable for preventing and treating hyperleptinemia | |
EP2714082A4 (de) | Verbindungen und verfahren zur behandlung von schmerzen | |
EP2718427A4 (de) | Zusammensetzungen und verfahren zur behandlung von glioblastomen | |
EP2800763A4 (de) | Zusammensetzungen und verfahren zur behandlung von multipler sklerose | |
GB201122124D0 (en) | Compositions and methods for treating biofilms | |
GB201104584D0 (en) | Compositions and methods for treating biofilms |